Quay Pharmaceuticals Sets Up Headquarters in Wales
North Wales - November 10, 2009
Quay Pharmaceuticals is investing £2.7million in a new headquarters and manufacturing facility in North Wales where, with support from the Welsh Assembly Government, it will create 54 new high quality jobs. Operations at the new site will include early stage research & development and clinical trials manufacturing for the global pharmaceutical and biotechnology industries.
Quay Pharma is a welcome addition to the healthcare and bioscience sector in Wales which employs some 15,000 people and is worth around £1.3billion annually to the Welsh economy. Support was provided through the Single Investment Fund to facilitate the company’s expansion programme, said Ieuan Wyn Jones, Minister for the Economy and Transport.
“Quay Pharma will be creating a range of high quality jobs over the next few years providing excellent employment opportunities for Welsh graduates,” said Wyn Jones.
The range of support offered by the Assembly Government to small and medium sized businesses had made Wales an attractive proposition for Quay Pharma’s expansion, Chief Executive Officer Mike Rubinstein said.
“The support from the Assembly Government is great for a small company and of particular help in the current economic climate. Not only does it provide advice and access to knowledge but also provides businesses with a high level of promotional and marketing support at overseas events," Rubenstein said.
The company is currently fitting out laboratories and offices with the aim of opening in January. The manufacturing operation is due to relocate during the first quarter of next year.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
